Aired 4 months ago 3:01
ardian Discussed on MedTech Talk Podcast
MedTech Talk Podcast
From the news
Aired 4 months ago 37:55
Gelfand and Levin Share Lessons from Ardians Rise and Falland Rise Again. Would They Do It Again?
Howard Levin and Mark Gelfand, the principals of Coridea, return to the podcast to detail the trials and tribulations of Ardian. Ardian is one of the bigger #medtech #startup stories over the past two decades. In 2011, Medtronic agreed to pay $800 million upfront for this company that pushed the once crazy idea of ablating renal nerves to lower hypertension. Ardian had raised $70 million from a syndicate of blue chip investors after being forged in the Foundry incubator. VCs proudly shared that the earnouts for Ardian would push that price well over $1 billion. This was a HUGE win for Medtech when it desperately needed it. Three years later came the fall. A day before JP Morganâ€™s Healthcare Meeting in 2014, Medtronic announced early disappointing of SYMPLICITY HTN-3, a third and larger trial of Ardianâ€™s renal denervation. Medtronic revised the trial, running Spryal HTN on patients who didnâ€™t take any medication for their hypertension â€“ a contrast from the Symplicity trial where patients were taking an average of five medications. In these revised trials, renal denervation is performing much better. The new results exonerated Ardianâ€™s early backers â€“ and perhaps Gelfand and Levin, specifically. This was the team, after all, that combed through medical libraries for clues about hacking the human body to beat back hypertension. The research turned up the discovery that surgeons once would treat extremely unresponsive hypertension by severing nerves near the kidney. The procedure worked, but it was dangerous. Levin and Gelfand saw ablating tissue as a safer path. And, after a lot of trudging up and down the Valley, finally found a willing partner in the team at The Foundry. Early clinical success led to a renal denervation gold rush. Nearly every VC and Strategic investor had a bet in this space. The 2014 debacle convinced many to close their programs and companies, but now Renal Denervation is back in favor. How did Howard Levin and Mark Gelfand enjoy the roller coaster ride? In this podcast, weâ€™ll talk about Ardian, TAVR, the challenges facing Medtech VCs and the poor reception many surgeons give new interventional technologies.
Aired 4 months ago 0:00
Mason and Ireland (HR 2)
Ramona Shelburne joins the guys and talks about the Lakers hiring Frank Vogel as head coach and Jason Kidd as asst. head coach. The guys discuss the NBA playoff and who has advanced to the conference finals.
Aired 1 year ago 35:36
Part 2: Product First? Or Audience First? - Ep #71
Part 2: Product First? Or Audience First? I talk about Strategy #2: Building an Audience First and THEN creating a product (ideally, productS) for that audience. Which is WAY easier said than done. And I'm also going to let you in on a little secret... that Strategy #1, which is Product First, Audience Next, and Strategy #2, which is Audience First, Product Next, are actually not mutually exclusive at all. You DON'T HAVE to choose just one or the other. You can actually do both. In fact, you MUST do both. But only in a certain order. And I'll talk about that in a second. Now to give you better context, I have to say this real quick about Strategy #1. The cool thing about Strategy #1, is that once you've accomplished that, then Strategy #2 - which is building an audience first - becomes kind of moot, because now you already have an existing audience who have already bought your first product. So creating additional products for an existing audience is going to be a lot easier than finding or building a new audience. I actually have a name for this: Go Deep, Then Wide. So when you find a niche where you have already created a product and you're starting to build up an audience in that niche, it is a lot easier to go deep into that niche, than to go wide, and start coming up with new niches that are unrelated to that product. Almost every single successful entrepreneur or company, almost always tends to go deep, before they go wide. Listen online at https://SubscribeMe.fm